Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2026-03-25 Share Issue/Capital Cha…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Capital Change Notice - Options Lapsed and Exercised - ASX
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse or cessation of certain securities (options) for Pacific Edge Limited. It includes specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is a formal announcement to the ASX regarding changes in the company's securities, specifically the cessation of certain options. This type of document is a regulatory announcement about changes in securities, which fits best under the category of Major Shareholding Notification (MRQ) or Share Issue/Capital Change (SHA). However, since it concerns cessation (lapse) of securities rather than new issues or capital changes, and it is a formal notification to the exchange about securities ceasing, the most appropriate classification is Share Issue/Capital Change (SHA), which covers announcements regarding share issues, stock splits, or other capital changes including cessation of securities. The document length is 4098 characters, which is short but contains detailed data, so it is not merely an announcement of a report but the actual notification itself. Therefore, the best fit is SHA.
2026-03-25 English
Capital Change Notice - Options Lapsed and Exercised
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Capital Change Notice' and details the lapse of options to acquire ordinary shares, including specific numbers, dates, and issuer information. It discusses capital changes such as issuance, acquisition, or redemption of financial products. There is no indication that this is a full financial report, earnings release, or management discussion. The content focuses on changes in the company's capital structure, specifically the lapse of options, which fits the definition of a Share Issue/Capital Change announcement. The document length is 4423 characters, which is concise but contains substantive details about capital changes, not just a brief announcement of a report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2026-03-25 English
Notification of cessation of securities - PEB 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for Pacific Edge Limited. It provides specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options. This type of announcement corresponds to a regulatory filing about securities cessation rather than a financial report or management discussion. Given the nature of the document and its content, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 4098 characters, which is relatively short and consistent with an announcement rather than a full report.
2026-03-24 English
Application for quotation of securities - PEB 6 pages 18.3KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used to apply for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, issue price, and whether the securities rank equally with existing securities. This type of document is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a capital market announcement about securities quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5736 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2026-03-24 English
First Triage Plus Tests Ordered from Townsville
Regulatory Filings Classification · 90% confidence The document is a press release announcing the adoption and clinical use of a medical diagnostic test (Cxbladder Triage Plus) at a hospital. It discusses clinical validation studies, guidelines, and the benefits of the test. There is no indication of financial data, regulatory filings, management changes, earnings, or any formal report. The content is informational about product adoption and clinical pathways, typical of a corporate announcement or update. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature and content, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-03-04 English
First Triage Plus Tests Ordered from Townsville 3 pages 166.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the adoption and clinical use of a medical diagnostic test (Cxbladder Triage Plus) at a hospital. It discusses clinical validation studies, guidelines, and the benefits of the test. There is no indication of financial data, regulatory filings, management changes, earnings, or any formal report. The content is promotional and informational about product adoption and clinical protocols, not a financial or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, Regulatory Filings, or others related to financial or corporate governance. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-03-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.